UBS Group’s Biogen BIIB Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $220K | Sell |
1,200
-47,500
| -98% | -$8.75M | ﹤0.01% | 6586 |
|
|
2025
Q4 | $8.57M | Buy |
48,700
+2,500
| +5% | +$408K | ﹤0.01% | 3449 |
|
|
2025
Q3 | $6.47M | Buy |
46,200
+1,000
| +2% | +$135K | ﹤0.01% | 3773 |
|
|
2025
Q2 | $5.68M | Sell |
45,200
-26,300
| -37% | -$3.28M | ﹤0.01% | 3744 |
|
|
2025
Q1 | $9.78M | Sell |
71,500
-56,300
| -44% | -$8.05M | ﹤0.01% | 3063 |
|
|
2024
Q4 | $19.5M | Buy |
127,800
+6,500
| +5% | +$1.1M | ﹤0.01% | 2343 |
|
|
2024
Q3 | $23.5M | Buy |
121,300
+14,300
| +13% | +$2.99M | 0.01% | 1697 |
|
|
2024
Q2 | $24.8M | Sell |
107,000
-44,600
| -29% | -$9.69M | 0.01% | 1508 |
|
|
2024
Q1 | $32.7M | Sell |
151,600
-55,800
| -27% | -$13.1M | 0.01% | 1335 |
|
|
2023
Q4 | $53.7M | Buy |
207,400
+16,600
| +9% | +$4.08M | 0.02% | 937 |
|
|
2023
Q3 | $49M | Buy |
190,800
+112,900
| +145% | +$30.2M | 0.02% | 863 |
|
|
2023
Q2 | $22.2M | Buy |
77,900
+6,500
| +9% | +$1.93M | 0.01% | 1376 |
|
|
2023
Q1 | $19.9M | Buy |
71,400
+26,900
| +60% | +$7.44M | 0.01% | 1401 |
|
|
2022
Q4 | $12.3M | Buy |
44,500
+17,230
| +63% | +$4.87M | ﹤0.01% | 1765 |
|
|
2022
Q3 | $7.28M | Buy |
27,270
+70
| +0.3% | +$14.9K | ﹤0.01% | 2040 |
|
|
2022
Q2 | $5.55M | Hold |
27,200
| – | – | ﹤0.01% | 2288 |
|
|
2022
Q1 | $5.73M | Sell |
27,200
-48,800
| -64% | -$10.6M | ﹤0.01% | 2408 |
|
|
2021
Q4 | $18.2M | Sell |
76,000
-37,298
| -33% | -$9.59M | 0.01% | 1649 |
|
|
2021
Q3 | $32.1M | Sell |
113,298
-10,500
| -8% | -$3.44M | 0.01% | 1129 |
|
|
2021
Q2 | $42.9M | Buy |
123,798
+8,440
| +7% | +$2.56M | 0.01% | 950 |
|
|
2021
Q1 | $32.3M | Buy |
115,358
+59,658
| +107% | +$16.1M | 0.01% | 1115 |
|
|
2020
Q4 | $13.6M | Buy |
55,700
+22,700
| +69% | +$5.86M | ﹤0.01% | 1617 |
|
|
2020
Q3 | $9.36M | Sell |
33,000
-3,000
| -8% | -$837K | ﹤0.01% | 1689 |
|
|
2020
Q2 | $9.63M | Sell |
36,000
-76,500
| -68% | -$23M | ﹤0.01% | 1535 |
|
|
2020
Q1 | $35.6M | Sell |
112,500
-32,000
| -22% | -$9.71M | 0.02% | 700 |
|
|
2019
Q4 | $42.9M | Buy |
144,500
+144,275
| +64,122% | +$40M | 0.01% | 858 |
|
|
2019
Q3 | $52K | Sell |
225
-17,375
| -99% | -$4.05M | ﹤0.01% | 6172 |
|
|
2019
Q2 | $4.12M | Sell |
17,600
-24,600
| -58% | -$5.68M | ﹤0.01% | 2491 |
|
|
2019
Q1 | $9.97M | Sell |
42,200
-118,800
| -74% | -$37.4M | ﹤0.01% | 1678 |
|
|
2018
Q4 | $48.4M | Buy |
161,000
+159,500
| +10,633% | +$50.9M | 0.02% | 606 |
|
|
2018
Q3 | $530K | Sell |
1,500
-1,800
| -55% | -$620K | ﹤0.01% | 4356 |
|
|
2018
Q2 | $958K | Sell |
3,300
-11,700
| -78% | -$3.29M | ﹤0.01% | 3811 |
|
|
2018
Q1 | $4.11M | Buy |
15,000
+5,000
| +50% | +$1.55M | ﹤0.01% | 2493 |
|
|
2017
Q4 | $3.19M | Sell |
10,000
-11,800
| -54% | -$3.79M | ﹤0.01% | 2773 |
|
|
2017
Q3 | $6.83M | Buy |
+21,800
| New | +$6.46M | ﹤0.01% | 1913 |
|
|
2017
Q2 | – | Sell |
-76,400
| Closed | -$20.9M | – | 7669 |
|
|
2017
Q1 | $20.9M | Buy |
76,400
+42,900
| +128% | +$12.1M | 0.01% | 1009 |
|
|
2016
Q4 | $9.5M | Sell |
33,500
-1,900
| -5% | -$563K | 0.01% | 1542 |
|
|
2016
Q3 | $11.1M | Sell |
35,400
-25,000
| -41% | -$7.4M | 0.01% | 1332 |
|
|
2016
Q2 | $14.6M | Buy |
60,400
+59,200
| +4,933% | +$15.6M | 0.01% | 1130 |
|
|
2016
Q1 | $312K | Sell |
1,200
-4,200
| -78% | -$1.11M | ﹤0.01% | 4159 |
|
|
2015
Q4 | $1.65M | Sell |
5,400
-3,500
| -39% | -$1.01M | ﹤0.01% | 2981 |
|
|
2015
Q3 | $2.6M | Buy |
8,900
+2,400
| +37% | +$793K | ﹤0.01% | 2508 |
|
|
2015
Q2 | $2.63M | Sell |
6,500
-14,400
| -69% | -$5.78M | ﹤0.01% | 2713 |
|
|
2015
Q1 | $8.82M | Buy |
20,900
+6,100
| +41% | +$2.4M | 0.01% | 1574 |
|
|
2014
Q4 | $5.02M | Buy |
+14,800
| New | +$4.79M | ﹤0.01% | 2085 |
|
Other funds holding BIIB
VCM
VPM
UBS Group's BIIB Position: Q1 2026 in Review
UBS Group reduced its Biogen (BIIB) stake by 18% in Q1 2026, selling an estimated $21.8M and leaving 523,450 shares worth $96M. The position accounts for 0.01% of the portfolio, ranked #1083.
UBS Group first reported a position in BIIB in Q4 2014 and has held it in 46 quarters since. The position peaked at $160M in Q4 2024. 1,004 funds tracked by Wall St. Rank hold BIIB as of Q1 2026.
- UBS Group held 523,450 shares of Biogen worth $96M as of Q1 2026.
- UBS Group sold 118,338 Biogen shares in Q1 2026, an estimated $21.8M.
- Biogen made up 0.01% of UBS Group's portfolio in Q1 2026, its #1083 holding.
- UBS Group first reported a position in Biogen in Q4 2014 and has held it in 46 quarters since.
- UBS Group's Biogen position peaked at $160M in Q4 2024.
- 1,004 funds tracked by Wall St. Rank held Biogen as of Q1 2026.
Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.